Table of contents
June 2013 - Volume 71 - Suppl 3
Annual European Congress of Rheumatology EULAR abstracts 2012, 6 – 9 June 2012, Berlin, Germany
- Speakers Abstracts
- Speaker Presentations
- Pre-conference outlook
- WIN Session 1
- Health economics of RA in 2012: Can we afford to treat? Can we afford not to treat?
- Interstitial lung disease in rheumatic disease: an update
- How to manage 1
- Long-term outcomes of modern treatment
- Seronegative rheumatoid arthritis
- Transition for teenagers and young adults with arthritis: what does it need?
- How to run an osteoarthritis clinic in daily practice
- Meet the ADAM’s family: ADAM, MMP’s, ADAMTS
- Talking microparticles
- Political campaigning
- Lupus in little and big folks
- “RADAR” – RAre Diseases Associated with Rheumatology
- How to manage 2
- Equitable or equal? To what or to whom? Equity issues in rheumatology
- Two difficult SLE patient cases
- Aseptic bone inflammation
- Crossing boundaries of primary to secondary care
- From joint development to osteoarthritis
- Fibroblasts transforming rheumatology
- MRI Workshop basic 1
- Less well-known but just as important: some “other” rare musculoskeletal diseases
- MicroRNA – macro effect
- New developments in the pre-clinical phases of rheumatoid arthritis
- WIN Session 2
- How to manage 3
- How to get a job and how to keep it
- Hot topics for primary care: what’s new?
- Vasculitis: new therapies changing outcomes
- Molecular targets for therapy in fibrotic diseases
- How to manage 4
- Soft predictors of hard outcomes
- Autoinflammation 2: Linking autoinflammation to autoimmunity
- Supporting self management in OA: the role of primary care
- Patient involvement in research. Past, present and future
- EULAR-EFIS Session: B regulatory cells
- Collateral damage in muscles
- MRI Workshop advanced 1
- What’s new: latest advances in treatment and management
- New insights in osteoarthritis
- How to manage 5
- Update on ACR/EULAR RA classification criteria: what have we learned?
- Underrecognized and challenging manifestations in systemic sclerosis
- Macrophage activation syndrome
- Work and workability in rheumatic diseases: what does it mean for primary care
- Promotion of physical activity in rheumatology targeting patients, providers and the public
- Immunological memory
- Innate lymphoid cells: straddling innate and adaptive immunity
- Comorbidity
- Bugs in autoimmunity
- Osteoimmunology: links to systemic and juvenile diseases
- WIN Session 5
- How to manage 6
- WIN Session 6
- SpA throughout life
- Vascular imaging in rheumatic diseases
- How to manage 7
- Patient Reported Outcome (PRO) assessment in rheumatology
- Multi-drug resistant RA
- Resolution and control of inflammation
- Primary and secondary care: working in partnership in autoimmune rheumatic diseases
- Challenges in health professionals, practice: how to develop and execute a treatment plan for a patient with a rheumatic condition and comorbidities
- Casting NET’s and catching autoimmunity: the role of neutrophils in inflammation
- Novel signalling molecules
- Impact of RMDs on families/partners/friends
- Non anti-TNF biologics on SpA and PsA
- How to implement technical improvements in existing imaging modalities in clinical practice
- It’s good but it may be dangerous
- Autoinflammation 1: News form IL-1 driven diseases
- Clinical update in connective tissue diseases
- New lights on translational models
- Biomechanics meets immunology (in spondyloarthritis)
- Working in partnership
- WIN Session 8
- RA treatment: small molecules
- Does everbody need stronger bones?
- Measuring outcomes in different settings
- Infections and arthritis
- I’ve been asked to review a clinical guideline – where do I start?
- Angiogenesis in health and disease
- Move, groove and improve – exercise and RMDs
- WIN Session 9
- RA remission: prediction and imaging
- ILAR – Advancing rheumatology in developing countries – ILAR projects – past, present and future
- How to manage 10
- Vaculitis
- Cardiovascular health in rheumatic diseases
- Auto antibodies actually cause disease: targeting the vasculature
- Breathing new life into rheumatology
- Inclusive design
- Health Professionals Highlight Session
- Speaker Presentations
- Scientific Abstracts
- Oral Presentations
- Interstitial lung disease in rheumatic disease: an update
- Long-term outcomes of modern treatment
- Transition for teenagers and young adults with arthritis: what does it need?
- Beginning and succeding as a clinical academic researcher
- EULAR criteria – work to improve rheumatologic care
- Political campaigning
- Equitable or equal? To what or to whom? Equity issues in rheumatology
- Aseptic bone inflammation
- From joint development to osteoarthritis
- Fibroblasts transforming rheumatology
- MicroRNA – macro effect
- New developments in the pre-clinical phases of rheumatoid arthritis
- Abstract Session: Update on non anti-TNF biologics
- Abstract Session: Osteoarthritis
- Abstract Session: Osteoporosis
- Abstract Session: RA prognosis, predictors, outcomes
- PReS Abstract Session: Basic science in paediatric rheumatology
- Abstract Session: Lupus and Sjögren’s; basics – diagnosis – treatment
- Abstract Session: Regional pain and fibromyalgia: understanding mechanisms and effective management
- HPR Abstract Session: Progress in rehabilitation – the future is bright
- Abstract Session: Early pathogenic mechanisms; clues for targeted therapies in arthritis
- Abstract Session: Spondyloarthritis – translational science
- Abstract Session: Metabolic and crystal diseases of joints and bone
- Abstract Session: Don’t forget the “orphans”
- Abstract Session: Epidemiololgy and health services
- How to get a job and how to keep it
- Vasculitis: new therapies changing outcomes
- Soft predictors of hard outcomes
- Personalised medicine
- New insights in osteoarthritis
- Update on ACR/EULAR RA classification criteria: what have we learned?
- Macrophage activation syndrome
- Work and workability in rheumatic diseases: what does it mean for primary care
- Immunological memory
- Comorbidity
- Osteoimmunology: links to systemic and juvenile diseases
- Abstract Session: RA anti-TNF
- Abstract Session: Treatment strategy in RA
- Abstract Session: Psoriatic arthritis
- Abstract Session: Spondyloarthritis – clinical aspects and treatment
- PReS Abstract Session: Clinical science in paediatric rheumatology
- Abstract Session: Vasculitis
- Primary Care Abstract Session: From epidemiology to effective practice
- HPR Abstract Session: Evidence into clinical practice – the way forward
- Abstract Session: Molecules – small and smart
- Abstract Session: Genomics, genetics and epigenetics of rheumatic diseases
- Abstract Session: Innate and adaptive immunity
- Abstract Session: Clincal and translational scleroderma
- Abstract Session: Diagnostics and imaging procedures
- PARE Abstract Session
- SpA throughout life
- Vascular imaging in rheumatic diseases
- Patient Reported Outcome (PRO) assessment in rheumatology
- Resolution and control of inflammation
- Primary and secondary care: working in partnership in autoimmune rheumatic diseases
- Casting NET’s and catching autoimmunity: the role of neutrophils in inflammation
- Novel signalling molecules
- Impact of RMDs on families/partners/friends
- Autoinflammation 1: News form IL-1 driven diseases
- Biomechanics meets immunology (in spondyloarthritis)
- RA treatment: small molecules
- Does everbody need stronger bones?
- Measuring outcomes in different settings
- Infections and arthritis
- EULAR–ESSR Session: Imaging in arthritis: the radiologist’s perspective
- Angiogenesis in health and disease
- Inhibitory checkpoints in inflammation
- RA remission: prediction and imaging
- Vaculitis
- Late Breaking Abstracts
- Poster Presentations
- Guided Poster Tours
- (Epi)-Genetics and genomics 1: where are we?
- Novel aspects of joint homeostasis and pathology
- B cells and beyond
- RA small molecules – old and new
- SLE, APS, Sjörgren’s
- Clinical scleroderma 1 and inflammatory myopathy
- Spondyloarthritis treatment
- PReS – basic research in paediatric rheumatology
- Orphan diseases and infectious arthritis
- Posters
- Genomics, genetics and epigenetics of rheumatic diseases
- Cartilage, synovium and osteoimmunology
- Rheumatoid arthritis – comorbidity and clinical aspects
- Rheumatoid arthritis – other biologic treatment
- Rheumatoid arthritis – non-biologic treatment and small molecules
- SLE, Sjögren’s and APS – clinical aspects (other than treatment)
- Vasculitis
- Scleroderma, myositis and related syndromes – clinical aspects and treatment
- Spondyloarthritis – treatment
- Basic science in paediatric rheumatology
- Paediatric rheumatology
- Fibromyalgia and pain in rheumatic diseases
- Infection-related rheumatic diseases
- Other orphan diseases
- Diagnostics and imaging procedures
- Education
- Guided Poster Tours
- RA prognosis, predictors, outcomes
- RA anti-TNF
- Vasculitis
- Clinical scleroderma 2
- Spondyloarthritis clinical aspects other than treatment
- Osteoarthritis
- PReS – clinical research in paediatric rheumatology
- Metabolic and crystal diseases of joints and bones
- Epidemiology and health services
- OT – PT (see page xiii)
- Posters
- Adaptative immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Cytokines and inflammatory mediators
- Rheumatoid arthritis – prognosis, predictors and outcome
- Rheumatoid arthritis – comorbidity and clinical aspects
- Rheumatoid arthritis – anti-TNF therapy
- Rheumatoid arthritis – other biologic treatment
- Vasculitis
- Scleroderma, myositis and related syndromes – clinical aspects and treatment
- Spondyloarthritis – clinical aspects (other than treatment)
- Osteoarthritis
- Paediatric rheumatology
- Bone diseases other than osteoporosis, metabolic diseases and crystal diseases
- Epidemiology, health services and outcome research
- Rehabilitation
- Guided Poster Tours
- (Epi)-Genetics and genomics 2: where are we?
- The mystery of SSc pathophysiology
- Pathogenesis of RA
- Lupus nephritis – bench to bedside
- Lupus and Sjörgren’s – clinical
- SpA – basic and translational highlights
- Psoriatic arthritis – from assessment to imaging
- Osteoporosis
- Diagnostics and imaging procedures
- Musculoskeletal health in Europe
- Posters
- Genomics, genetics and epigenetics of rheumatic diseases
- Scleroderma, myositis and related syndromes – etiology, pathogenesis and animal models
- Rheumatoid arthritis – etiology, pathogenesis and animal models
- Rheumatoid arthritis – prognosis, predictors and outcome
- Rheumatoid arthritis – anti-TNF therapy
- SLE, Sjögren’s and APS – etiology, pathogenesis and animal models
- SLE, Sjögren’s and APS – treatment
- SLE, Sjögren’s and APS – clinical aspects (other than treatment)
- Spondyloarthritis – etiology, pathogenesis and animal models
- Spondyloarthritis – clinical aspects (other than treatment)
- Psoriatic arthritis
- Osteoarthritis
- Osteoporosis
- Diagnostics and imaging procedures
- Back pain, mechanical musculoskeletal problems, local soft tissue disorders
- Epidemiology, health services and outcome research
- Guided Poster Tours
- Abstracts accepted for publication
- Genomics, genetics and epigenetics of rheumatic diseases
- Adaptative immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Cytokines and inflammatory mediators
- Cartilage, synovium and osteoimmunology
- Rheumatoid arthritis – etiology, pathogenesis and animal models
- Spondyloarthritis – etiology, pathogenesis and animal models
- SLE, Sjögren’s and APS – etiology, pathogenesis and animal models
- Scleroderma, myositis and related syndromes – etiology, pathogenesis and animal models
- Basic science in paediatric rheumatology
- Rheumatoid arthritis – prognosis, predictors and outcome
- Rheumatoid arthritis – comorbidity and clinical aspects
- Rheumatoid arthritis – anti-TNF therapy
- Rheumatoid arthritis – other biologic treatment
- Rheumatoid arthritis – non-biologic treatment and small molecules
- SLE, Sjögren’s and APS – treatment
- SLE, Sjögren’s and APS – clinical aspects (other than treatment)
- Vasculitis
- Scleroderma, myositis and related syndromes – clinical aspects and treatment
- Spondyloarthritis – treatment
- Spondyloarthritis – clinical aspects (other than treatment)
- Psoriatic arthritis
- Osteoarthritis
- Osteoporosis
- Bone diseases other than osteoporosis, metabolic diseases and crystal diseases
- Infection-related rheumatic diseases
- Fibromyalgia and pain in rheumatic diseases
- Back pain, mechanical musculoskeletal problems, local soft tissue disorders
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Epidemiology, health services and outcome research
- Rehabilitation
- Education
- Oral Presentations
- Primary Care Abstracts
- Health Professionals in Rheumatology Abstracts
- People with Arthritis and Rheumatism in Europe Abstracts